BioVaxys is a clinical-stage biopharma developing antiviral & anticancer vaccine platforms. The Company is evaluating a potential SARS-CoV-2 vaccine based on its haptenized viral protein technology, and advancing a compassionate use trial in the EU to evaluate its haptenized cell vaccine for late-stage ovarian cancer. In addition to our haptenized cell vaccines for ovarian cancer and other tumor types, we are exploring ways we...
BioVaxys is a clinical-stage biopharma developing antiviral & anticancer vaccine platforms. The Company is evaluating a potential SARS-CoV-2 vaccine based on its haptenized viral protein technology, and advancing a compassionate use trial in the EU to evaluate its haptenized cell vaccine for late-stage ovarian cancer. In addition to our haptenized cell vaccines for ovarian cancer and other tumor types, we are exploring ways we can leverage our technology platform in the field of Adoptive Immunotherapy, which is also of significant interest in the immune-oncology market.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.